文献速递免疫规划

通过传染病建模比较水痘疫苗的性能

Comparison of performance of varicella vaccines via infectious disease modeling.
PubMed 文献 · Vaccine · 2022-05-31

研究利用确定性房室模型模拟Varivax®(V-MSD)和Varilrix®(V-GSK)水痘疫苗一剂或两剂接种的临床试验,拟合突破性感染数据并比较模型拟合优度。估计首剂V-MSD后90.3%(95%CI:87.8-92.9%)的队列获得永久保护,V-GSK为61.7%(95%CI:58.2-65.3%);两剂后V-MSD和V-GSK分别为97.0%(95%CI:95.2-98.8%)和93.8%(95%CI:92.2-95.4%)。新模型拟合优于现有模型。

要点

  • 首剂V-MSD后90.3%的队列获得永久保护,V-GSK为61.7%。
  • 两剂后V-MSD和V-GSK的永久保护比例分别为97.0%和93.8%。
  • 新模型AIC(V-MSD 92.7;V-GSK 170.3)优于现有模型。

核心结论

  • 新模型能拟合V-MSD和V-GSK的长期临床试验突破性感染数据,从而允许直接比较疫苗性能。
  • 估计单剂V-MSD比单剂V-GSK更可能提供永久保护,而两剂疫苗提供的保护相似。

研究设计与样本

  • 使用确定性房室模型模拟Varivax®(V-MSD)和Varilrix®(V-GSK)一剂或两剂水痘疫苗接种的临床试验。
  • 拟合临床试验突破性感染数据,并使用赤池信息准则(AIC)评估模型拟合优度。

主要发现

  • 基于临床试验数据,估计首剂V-MSD后90.3%(95%CI:87.8-92.9%)的队列获得对突破性水痘的永久保护,而首剂V-GSK后为61.7%(95%CI:58.2-65.3%)。
  • 估计两剂V-MSD和V-GSK后分别有97.0%(95%CI:95.2-98.8%)和93.8%(95%CI:92.2-95.4%)的队列获得永久保护。
  • 根据AIC,新模型(V-MSD AIC=92.7;V-GSK AIC=170.3)比现有模型(V-MSD AIC=108.9;V-GSK AIC=216.1)拟合更好。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Population-level infectious disease models for varicella require vaccine parameters, namely 'take' and 'duration of protection' (defined here as vaccine performance), to quantify the impact of vaccination. Current published models for varicella use vaccine parameters derived from various methodologies which does not allow for the direct comparison of different vaccines. METHODS: We estimated take and duration of protection using deterministic compartmental models to simulate clinical trials of one- or two-dose varicella vaccination using Varivax® (V-MSD) and Varilrix® (V-GSK). We fit different models to clinical trial data on breakthrough infections and evaluated their respective goodness-of-fit using the Akaike Information Criterion (AIC). RESULTS: Based upon the clinical trial data, we estimated that 90.3% (95% CI: 87.8-92.9%) of the cohort gained permanent protection from breakthrough varicella after the first dose of V-MSD compared to 61.7% (95% CI: 58.2-65.3%) with the first dose of V-GSK. We further estimated that a total of 97.0% (95% CI: 95.2-98.8%) and 93.8% (95% CI: 92.2-95.4%) of the cohort were permanently protected after two-doses of V-MSD and V-GSK, respectively. According to the AIC, our new model (V-MSD AIC = 92.7; V-GSK AIC = 170.3) provided a better fit than an existing model (V-MSD AIC = 108.9; V-GSK AIC = 216.1). CONCLUSIONS: The model developed fits the long-term clinical trial data on breakthrough infections for both V-MSD and V-GSK, thus, allowing for the direct comparison of vaccine performance. We estimated that a single dose of V-MSD was more likely to provide permanent protection than a single dose of V-GSK, while the protection offered by two doses was similar for both vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pillsbury M, Carias C, Samant S, et al. Comparison of performance of varicella vaccines via infectious disease modeling. Vaccine. 2022. PMID: 35660037. doi:10.1016/j.vaccine.2022.05.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。